Novartis AG (NVS)

70.43
0.00 (0.00)
NYSE : Health Care
Prev Close 70.43
Open 70.42
Day Low/High 70.41 / 70.57
52 Wk Low/High 66.93 / 83.58
Volume 121.73K
Avg Volume 3.46M
Exchange NYSE
Shares Outstanding 2.38B
Market Cap 171.01B
EPS 7.40
P/E Ratio 19.43
Div & Yield 2.72 (3.80%)

Latest News

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

Jim Cramer says he's still 'a believer' in KKR and Opko.

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Stocks kept rallying right through and after this rate hike, says Jim Cramer.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Ophthotech Plunges on Eye-Drug-Study Failure

Ophthotech Plunges on Eye-Drug-Study Failure

Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.

Financials and Tech Shares Lift Wall Street; Dow Hits Record High

Financials and Tech Shares Lift Wall Street; Dow Hits Record High

The Dow trades at an all-time high Monday as the financial and energy sectors rise.

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Dow Sets Record High as Oil Maintains Momentum

Dow Sets Record High as Oil Maintains Momentum

The Dow trades at an all time high Monday as crude oil climbs higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.

Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains

Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains

Stock futures rise Monday as crude oil continues to climb higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

Wall Street scores a trifecta of record closes on Monday as a crude oil rally gives stocks an across-the-board boost.